Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Saridegib |
| Trade Name | |
| Synonyms | IPI-926|IPI926|Patidegib |
| Drug Descriptions |
Saridegib (IPI-926) is a Smoothened (SMO) antagonist that inhibits downstream signaling, potentially resulting in decreased growth of tumors with dysregulation of Hedgehog pathway signaling (PMID: 19522463,PMID: 26390428, PMID: 24608250). |
| DrugClasses | SMO Inhibitor 16 |
| CAS Registry Number | 1037210-93-7 |
| NCIT ID | C80063 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Saridegib | Fluorouracil Irinotecan Leucovorin Oxaliplatin Saridegib | 0 | 1 |
| Saridegib | Saridegib | 0 | 0 |
| Saridegib + Sorafenib | Saridegib Sorafenib | 1 | 0 |